L. Renshaw

发表

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

G. Hampton, J. Dixon, W. Miller, 2007, Pharmacogenetics and genomics.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Jeffrey M. Rosen, Charles M. Perou, Susan G. Hilsenbeck, 2009, Proceedings of the National Academy of Sciences.

MolecularChanges inLobularBreastCancers inResponse to Endocrine Therapy

A. Turnbull, Jeremy S. Thomas, J. Dixon, 2014 .

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

J. Dixon, K. Cheung, Julie Morris, 2010, Clinical Cancer Research.

DCIS and aromatase inhibitors

J. Dixon, D. Faratian, Jeremy S. Thomas, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Surgical issues surrounding use of aromatase inhibitors

J. Dixon, W. Miller, L. Renshaw, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

W. Miller, J. Dixon, T. Anderson, 2006, British Journal of Cancer.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

T. Sing, W. Miller, J. Dixon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

M. Dowsett, R. A’Hern, E. Folkerd, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer

T. Wilson, J. Dixon, A. Turnbull, 2014, Breast Cancer Research and Treatment.

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women

M. Dowsett, J. Dixon, J. Dixon, 2009, Breast Cancer Research and Treatment.

P097. Intra-operative assessment of excision margins in breast conserving surgery for breast cancer using ClearEdge imaging device

J. Dixon, Jeremy S. Thomas, J. Keys, 2015 .

Intra-operative assessment of excised breast tumour margins using ClearEdge imaging device.

J. Dixon, L. Williams, C. Kusnick, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

M. Ellis, M. Dowsett, Y. Tao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Expression Profiles of Endocrine Resistant Breast Tumours.

D. Faratian, J. Dixon, A. Larionov, 2009 .

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

M. Dowsett, D. Cameron, J. Dixon, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer

J. Dixon, J. Dixon, L. Renshaw, 2010, Breast Cancer Research and Treatment.

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.

J. Dixon, D. Faratian, L. Renshaw, 2008, European journal of cancer.

Src inhibitors in early breast cancer: a methodology, feasibility and variability study

P. Elvin, J. Dixon, C. Womack, 2009, Breast Cancer Research and Treatment.

Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability

L. Fallowfield, J. Dixon, J. Dixon, 2011, Breast Cancer Research and Treatment.

Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.

M. Dowsett, D. Cameron, J. Dixon, 2004, European journal of cancer.

Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.

J. Dixon, L. Renshaw, E. J. Macaskill, 2006, The oncologist.

S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.

Minetta C. Liu, R. Clarke, Yue Wang, 2011 .

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer

C. Perou, Xiaping He, J. Parker, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular changes in lobular breast cancers in response to endocrine therapy.

A. Turnbull, J. Dixon, C. Kay, 2014, Cancer research.

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer

J. Dixon, A. Sims, L. Renshaw, 2010, Breast Cancer Research and Treatment.

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

M. Ranson, J. Dixon, A. Wardley, 2010, Breast Cancer Research and Treatment.

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

A. Turnbull, J. Dixon, A. Sims, 2018, Breast Cancer Research.

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

J. Bartlett, J. Dixon, D. Faratian, 2011, Breast Cancer Research and Treatment.

Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies

J. Bartlett, A. Turnbull, J. Dixon, 2016, Scientific Reports.

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer

M. Dowsett, J. Reis-Filho, Z. Ghazoui, 2015, Breast Cancer Research.

Invasive lobular carcinoma: response to neoadjuvant letrozole therapy

J. Dixon, L. Renshaw, J. Thomas, 2011, Breast Cancer Research and Treatment.

Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches

Charles M. Perou, Carlos Martinez-Perez, Richard Clark, 2020, BMC Bioinformatics.

Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis

R. Kitchen, A. Turnbull, A. Larionov, 2012, BMC Medical Genomics.

Aromatase inhibitors—Gene discovery

G. Hampton, W. Miller, J. Dixon, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

M. Dowsett, A. Turnbull, J. Dixon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increase in response rate by prolonged treatment with neoadjuvant letrozole

David Cameron, G. Kerr, D. Cameron, 2008, Breast Cancer Research and Treatment.

The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.

J. Dixon, W. Miller, C. Bellamy, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lessons from the use of aromatase inhibitors in the neoadjuvant setting.

D. Cameron, J. Dixon, W. Miller, 1999, Endocrine-related cancer.

Transcriptional profiling of patient-matched ER-positive breast cancer tissue from post-menopausal women treated with neoadjuvant RAD001

J. Dixon, A. Sims, L. Renshaw, 2009 .

Priority Report MolecularChanges inLobularBreastCancers inResponse to Endocrine Therapy

A. Turnbull, J. Dixon, C. Kay, 2014 .

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models

P. Lambin, L. Dubois, C. Supuran, 2015, Oncotarget.

Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles

Jano I van Hemert, R. Kitchen, J. Bartlett, 2010, BMC Genomics.

Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies

Baljit Singh, F. Baehner, D. Cameron, 2019, Advances in Therapy.

Factors affecting cosmetic outcome after breast conserving surgery

J. Dixon, L. Renshaw, R. Macmillan, 2001 .

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes

J. Dixon, W. Miller, L. Renshaw, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

GENE EXPRESSION PROFILING OF ER-POSITIVE BREAST TUMOURS FROM POST-MENOPAUSAL WOMEN TREATED WITH NEOADJUVANT RAD001

J. Dixon, A. Sims, L. Renshaw, 2009 .

Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches

C. Perou, Xiaping He, L. Carey, 2020, BMC Bioinformatics.

Mutation of PI3KCA in post-menopausal women with breast cancer and response to RAD001 treatment.

J. Bartlett, J. Dixon, L. Renshaw, 2009 .

Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer.

M. Dowsett, D. Cameron, E. Folkerd, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CCR-21-3189 3618..3629

C. Perou, Xiaping He, J. Parker, 2022 .

Mondor's disease of the breast: A cutaneous thromboembolic manifestation of Covid-19?

A. Turnbull, J. Dixon, L. Renshaw, 2022, The Breast.

A randomised study of the impact of endocrine therapy for breast cancer on bone turnover and quality of life

J. Dixon, L. Renshaw, J. Murray, 2008 .

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

K. Cheung, G. Landberg, N. Bundred, 2010, Clinical Cancer Research.

Estrogen-independent cell proliferation occurs in the majority of estrogen receptor positive (ER+)/HER2 gene-amplified primary breast cancers: Evidence from a combined analysis of two independent neoadjuvant letrozole studies

M. Ellis, Y. Tao, W. Miller, 2005 .

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

M. Dowsett, D. Cameron, R. A’Hern, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.